“One Stop Solution – Gene to Protein to Antibody”
A "DSIR Recognized" Research Based Company
Recognized as Place of research
History and Milestone
-
2011
Incorporation
-
2013
-
2014BIG-BIRAC
(~ 5 Million INR) -
2015
Indo-French CEFIPRA
(~1 Million) -
2016
Recombinant Antibody Platform Developed Range of Products
-
2017
Two Patents from Development
-
2018
WiNER Award
(~0.5 Million INR) -
2018
Technology Hotspot Award at Select Bio
-
2019
BIRAC-PACE Grant
(~ 5 Million INR) -
2019
ISO 9001: 2015 Quality Management Certification
-
National Biopharma Mission
(~ 10 Million INR) -
DSIR Accredition MoST, GOI
-
Samriddhi Grant
A "DSIR Recognized" Research Based Company - GeNext Genomics
About Us
Established in 2011, Genext Genomics Pvt Ltd is an emerging life science research start up and contract research organization in central india, with focus on providing purpose-based solution for life science customers, a one stop solution for all your protein needs! Founded and managed by a team of scientists with extensive experience in both academia and industry, GNG is working for development of recombinant proteins and monoclonal antibodies against clinically relevant targets through the integration of bioinformatics, recombinant DNA technology, proteomics and immunology using novel high-throughput technologies.
GeNext Genomics offers a wide range of services that complement your research and accelerate the process from development to clinical use.
Our Services
ANTIBODY LIBRARY SERVICES
GeNext Genomics has proprietary phage display library for production of high affinity monoclonal antibodies and has been specialized in applying the technologies for wide range of service project.
RECOMBINANT PROTEINS EXPRESSION AND PURIFICATION
Cloning the gene, Sub cloning in the expression vector, Upstream- expression and purification at analytical scale; downstream process – scale up
MONOCLONAL ANTIBODIES PRODUCTION
Immunization of antigen, fusion, Production of hybridoma, Single cell cloning, Mab production
RECOMBINANT ANTIBODY SERVICES
Cloning scfv in E.Coli expression vector, Cloning of full IgG in CHO expression system
Contact us and receive a quote within 24 hours
Our Latest News Updates
June 7, 2022
Nine Biopharma Trends to Watch in 2022
Biomedical breakthroughs in recent years have been revolutionary, and they are likely to cause substantial industry[…]
June 7, 2022
Advantages of Hybridoma vs Phage Display for Monoclonal Antibody Production
What level of antibody affinity do you require? What will your project’s final application be? Do[…]
June 6, 2022
Production of Monoclonal Antibodies
The definitive monoclonal antibody (mAb) production procedure involves fusing myeloma cells with desired antibody-producing splenocytes[…]